drugset / Trial / NCT06899230
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007. iQ-007 may be indicated for use in patients with Focal Seizures and Drug-resistant Epilepsy (DRE).
Timeline
- Start
- 2025-04-08
- Primary completion
- 2026-01-29
- Completion
- 2026-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iQ-007 | Unknown | 200 mg | Oral |
| Subject | iQ-007 | Unknown | 600 mg | Oral |
| Subject | iQ-007 | Unknown | 2400 mg | Oral |
| Subject | iQ-007 | Unknown | 2800 mg | Oral |